Osteopore (ASX:OSX) reported the early cessation of its AU$18.7 million dental grant clinical-industrial partnership project after a strategic review, according to a Thursday Australian bourse filing.
The decision will allow for a reallocation of resources and align with its near- and mid-term objectives of prioritizing commercialization.
The firm had been looking for opportunities to improve cost center performance while at the same time streamlining expenses.
Its shares rose 10% on market close on Thursday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。